An HIV drug failed to help patients with severe cases of COVID-19, according to disappointing results from one of the first coronavirus drug trials

United States News News

An HIV drug failed to help patients with severe cases of COVID-19, according to disappointing results from one of the first coronavirus drug trials
United States Latest News,United States Headlines
  • 📰 YahooNews
  • ⏱ Reading Time:
  • 59 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 27%
  • Publisher: 59%

Kaletra is one of several existing drugs that are being tested as repurposed coronavirus treatments.

A 'heroic effort' with a 'disappointing' ending, the journal's editor in chief Eric Rubin and deputy editor Lindsey Baden applauded the scientists for running this study under the extraordinary pressure of an epidemic.

"This was a heroic effort," Rubin and Baden wrote."Health care workers in Hubei province have provided patient care in an overwhelming epidemic while they themselves are one of the highest risk groups for development of disease." In answering why Kaletra didn't work, they write that this trial focused on a"particularly challenging patient population" and the HIV drug isn't especially potent against this novel coronavirus.

The patient group had a median age of 58 years old and typically had started to develop symptoms 13 days before first receiving treatment. For both groups, those on Kaletra and those not taking it, it took 16 days on average to see clinical improvement. While the study's main goal was to test to see if Kaletra could speed up the time to clinical improvement, researchers tracked a range of other metrics that may show some benefit.

Patients on Kaletra had a median time in the intensive care unit of 6 days compared to 11 days for the control group. For the slice of patients that were treated within 12 days of developing symptoms, Kaletra did appear to help them get better.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

YahooNews /  🏆 380. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

My Cheating Co-Worker Had an HIV Scare but Keeps Taking “Long Lunches.” Should I Tell Her Husband?My Cheating Co-Worker Had an HIV Scare but Keeps Taking “Long Lunches.” Should I Tell Her Husband?Dear How to Do It: My cheating co-worker keeps taking “long lunches,” despite an HIV scare. I’m friends with her husband too.
Read more »

Photos: Volunteers in Seattle get first doses of trial vaccine for COVID-19Photos: Volunteers in Seattle get first doses of trial vaccine for COVID-19The first shots in the first vaccine trial for the new coronavirus were administered as a small group of volunteers in Seattle will receive varying doses over the next several weeks.
Read more »

West Virginia Announces Its First Coronavirus Case, Becoming Last State to Have Positive COVID-19 TestWest Virginia Announces Its First Coronavirus Case, Becoming Last State to Have Positive COVID-19 TestAs of Tuesday evening, all 50 U.S. states have at least one confirmed case of COVID-19 within its borders
Read more »

Tom Hanks Says His 'Symptoms Are Much the Same' a Week After Coronavirus DiagnosisTom Hanks Says His 'Symptoms Are Much the Same' a Week After Coronavirus DiagnosisTom Hanks and wife Rita Wilson tested positive for the COVID-19 coronavirus while in Australia
Read more »

Here’s Exactly What Medical Experts Mean by “Shortness of Breath”Here’s Exactly What Medical Experts Mean by “Shortness of Breath”The Centers for Disease Control and Prevention and the World Health Organization list it as one of the primary symptoms of the coronavirus.
Read more »

Amid The Coronavirus Outbreak, Here’s What Forbes Is Doing New To Keep You InformedAmid The Coronavirus Outbreak, Here’s What Forbes Is Doing New To Keep You InformedWe recognize that the new coronavirus and COVID-19 presents one of the most serious challenges we’ve ever faced in two areas central to why people turn to Forbes: science and business.
Read more »



Render Time: 2025-03-06 23:41:24